Skip to content
← All treatment topics

TREATMENT READING

Childhood Central Nervous System Germ Cell Tumors

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

34 sections
  1. Treatment Option Overview for Childhood CNS Germ Cell Tumors
  2. Treatment of Newly Diagnosed Childhood CNS Germinomas
  3. Neoadjuvant Chemotherapy Followed by Response-Based Radiation Therapy
  4. Radiation Therapy
  5. Treatment Options Under Clinical Evaluation for Newly Diagnosed Childhood CNS Germinomas
  6. Treatment of Newly Diagnosed Childhood CNS Nongerminomatous Germ Cell Tumors
  7. Chemotherapy Followed by Radiation Therapy
  8. Surgery
  9. Treatment Options Under Clinical Evaluation for Newly Diagnosed Childhood CNS NGGCTs
  10. Treatment of Newly Diagnosed Childhood CNS Teratomas
  11. Gross-Total Resection
  12. Treatment of Recurrent Childhood CNS Germ Cell Tumors
  13. Chemotherapy Followed by Additional Radiation Therapy
  14. High-Dose Chemotherapy With Stem Cell Rescue With or Without Additional Radiation Therapy
  15. Treatment Options Under Clinical Evaluation for Recurrent Childhood CNS GCTs
  16. Sometimes childhood central nervous system germ cell tumors come back after treatment.
  17. Treatment Option Overview
  18. Key Points
  19. There are different types of treatment for children with central nervous system (CNS) germ cell tumors.
  20. Children with CNS germ cell tumors should have their treatment planned by a team of health care providers who are experts in treating cancer in children.
  21. The following types of treatment are used:
  22. Radiation therapy
  23. Chemotherapy
  24. Surgery
  25. High-dose chemotherapy with stem cell rescue
  26. New types of treatment are being tested in clinical trials.
  27. Treatment for childhood CNS germ cell tumors may cause side effects.
  28. Patients may want to think about taking part in a clinical trial.
  29. Patients can enter clinical trials before, during, or after starting their cancer treatment.
  30. Follow-up care may be needed.
  31. Treatment of Childhood CNS Germinomas
  32. Treatment of Childhood CNS Nongerminomas
  33. Treatment of Childhood CNS Teratomas
  34. Treatment of Recurrent Childhood CNS Germ Cell Tumors

Health professional

Treatment Option Overview for Childhood CNS Germ Cell Tumors

Source: Childhood Central Nervous System Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: October 8, 2024. Captured 2026-09-09.

Teratomas, germinomas, and other nongerminomatous germ cell tumors (NGGCTs) have differing prognoses and require different treatment regimens. Studies have observed the following:[1-5]

Sources: 1 · 5

For children older than 3 years and adults, radiation therapy has been an important component of therapy for germinomas and NGGCTs, although the optimal dose and field of irradiation are debated.

Central nervous system (CNS) germ cell tumors (GCTs), similar to gonadal and extragonadal GCTs, have demonstrated sensitivity to chemotherapy.

Germinomas are highly chemosensitive and radiosensitive tumors. They are curable with craniospinal irradiation and local site–boost radiation therapy alone. However, the use of neoadjuvant or preirradiation chemotherapy allows reduced radiation therapy doses and volumes and, subsequently, reduced long-term radiation therapy–related effects.

In North America and Europe, patients with localized germinomas are effectively treated with whole-ventricular irradiation supplemented with tumor site–boost radiation therapy. Focal irradiation to the tumor bed, regardless of response to chemotherapy, is considered inadequate treatment.[6]

Sources: 6

For NGGCTs, the combined use of more intensive neoadjuvant chemotherapy followed by either localized or craniospinal irradiation has resulted in improved survival rates in the last decade.[5,7,8]

Sources: 5 · 7 · 8

Patients with bifocal intracranial GCTs limited to the suprasellar and pineal region were treated in the same manner as patients with localized, nonmetastatic tumors in studies in North America and Europe.[8]

Sources: 8

Table 3 outlines the treatment options for patients with newly diagnosed and recurrent childhood CNS GCTs.

Sources: Table 3

Table 3. Treatment Options for Childhood Central Nervous System (CNS) Germ Cell Tumors (GCTs)
Treatment GroupTreatment Options
Newly diagnosed childhood CNS germinomasNeoadjuvant chemotherapy followed by response-based radiation therapy
Radiation therapy
Newly diagnosed childhood CNS nongerminomatous GCTsChemotherapy followed by radiation therapy
Surgery, if incomplete response to chemotherapy before irradiation
Newly diagnosed childhood CNS teratomasGross-total resection
Recurrent childhood CNS GCTsChemotherapy followed by additional radiation therapy
High-dose chemotherapy with stem cell rescue with or without additional radiation therapy

Sources: Neoadjuvant chemotherapy followed by response-based radiation therapy · Radiation therapy · Chemotherapy followed by radiation therapy · Surgery, if incomplete response to chemotherapy before irradiation · Gross-total resection · Chemotherapy followed by additional radiation therapy · High-dose chemotherapy with stem cell rescue with or without additional radiation therapy

Dramatic improvements in survival have been achieved for children and adolescents with cancer. Between 1975 and 2010, childhood cancer mortality decreased by more than 50%.[9] Childhood and adolescent cancer survivors require close monitoring because side effects of cancer therapy may persist or develop months or years after treatment. For information about the incidence, type, and monitoring of late effects in childhood and adolescent cancer survivors, see Late Effects of Treatment for Childhood Cancer.

Sources: 9 · Late Effects of Treatment for Childhood Cancer

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

Health professional

Treatment of Newly Diagnosed Childhood CNS Germinomas

Source: Childhood Central Nervous System Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: October 8, 2024. Captured 2026-09-09.

Treatment options for newly diagnosed childhood central nervous system (CNS) germinomas include the following:

Neoadjuvant chemotherapy followed by response-based radiation therapy.

Sources: Neoadjuvant chemotherapy followed by response-based radiation therapy

Radiation therapy.

Sources: Radiation therapy

Health professional · Treatment of Newly Diagnosed Childhood CNS Germinomas

Neoadjuvant Chemotherapy Followed by Response-Based Radiation Therapy

Source: Childhood Central Nervous System Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: October 8, 2024. Captured 2026-09-09.

Chemotherapy has been explored to reduce radiation therapy doses and associated neurodevelopmental morbidity. Several studies have confirmed the feasibility of this approach for maintaining excellent survival rates.[1-4][Level of evidence B4]; [5-8][Level of evidence C1]

Sources: 1 · 4 · Level of evidence B4 · 5 · 8 · Level of evidence C1

Chemotherapy agents such as cyclophosphamide, ifosfamide, etoposide, cisplatin, and carboplatin are highly active in CNS germinomas. Managing patients receiving chemotherapy agents that require hyperhydration (e.g., cyclophosphamide, ifosfamide, and cisplatin) can be quite challenging because of the possibility of diabetes insipidus in patients with primary tumors of the suprasellar region.[9]

Sources: 9

An international group of investigators explored a chemotherapy-only approach primarily for younger children. A complete response was achieved in 84% of patients with germinomas who were treated with chemotherapy alone. However, 50% of these patients suffered tumor relapse or progression. Many recurrences were local, local plus ventricular, and ventricular alone and/or with leptomeningeal dissemination throughout the CNS, which required additional therapy, including radiation.[10]

Sources: 10

Subsequent studies have continued to support the need for radiation therapy after chemotherapy and the likely requirement for whole-ventricular irradiation (24 Gy) with local tumor site–boost radiation therapy (total dose, 40 Gy).[11][Level of evidence B4]; [12][Level of evidence C1] Excellent results have also been reported for patients with metastatic germinomas who received craniospinal irradiation of 24 Gy with local tumor site–boost radiation therapy (total dose, 40 Gy).[1][Level of evidence B4]; [13]

Sources: 11 · Level of evidence B4 · 12 · Level of evidence C1 · 1 · Level of evidence B4 · 13

Optimal management of bifocal lesions is less clear, but most investigators consider this presentation a form of metachronous primary disease to be staged as M0. A meta-analysis of 60 patients demonstrated excellent progression-free survival after craniospinal irradiation alone. Chemotherapy plus localized radiation therapy, including whole-ventricular irradiation, also resulted in excellent disease control.[14][Level of evidence C2] For germinomas that arise outside of the pineal or suprasellar region, the effectiveness of therapy, as used for pineal and/or suprasellar lesions, is not well delineated. However, one retrospective review of 47 patients with basal ganglion and thalamic tumors reported progression-free survival (PFS) and overall survival (OS) rates that were similar to those reported in patients with tumors arising in more common areas of the brain.[15]

Sources: 14 · Level of evidence C2 · 15

Results have been reported for the ACNS1123 (NCT01602666) phase II trial (stratum 2) that investigated response-based radiation therapy for localized germinomas. Patients were aged 3 to 21 years. Patients who had a complete response to carboplatin and etoposide chemotherapy received 18 Gy of whole-ventricle irradiation and a 12-Gy boost to the tumor bed. Patients who had a partial response to chemotherapy proceeded to receive 24 Gy of whole-ventricle irradiation and a 12-Gy boost to the tumor bed. Longitudinal cognitive functioning was evaluated prospectively. There were 137 eligible patients. Among 90 evaluable patients, 74 were treated with 18 Gy of radiation, and 16 were treated with 24 Gy of whole-ventricle irradiation.[16]

Sources: ACNS1123 (NCT01602666) · 16

The study failed to demonstrate noninferiority of the 18 Gy whole-ventricle irradiation regimen, compared with the study-specified threshold of a 95% 3-year PFS rate. The analysis was confounded by including any patient who could not be assessed for progression at 3 years as a treatment failure, which lead to a PFS rate of 86%. If these patients who could not be assessed were excluded, the Kaplan-Meier–based 3-year PFS estimates were 94.5% (± 2.7%) for the 18 Gy cohort.

Collectively, estimated mean IQ, attention, and concentration were within normal range. A lower mean attention score was observed at 9 months for patients who were treated with 24 Gy of radiation. Acute effects in processing speed were observed for patients who were treated with 18 Gy at 9 months, which improved at the 30-month assessment. However, the sample size was small and did not account for confounding variables such as surgical complications, hydrocephalus, and limited long-term follow-up data.

None of the evaluable patients had a relapse within the ventricular field or in the primary tumor region. All four disease progressions occurred outside of the radiation field, at a median time of 8.91 months after radiation therapy.

Of the eight relapses, three occurred along the biopsy tract.

Residual disease at the end of treatment was not associated with a worse prognosis.

Other studies have supported this treatment approach, reporting excellent outcomes in children with CNS germinomas.[17,18]

Sources: 17 · 18

Health professional · Treatment of Newly Diagnosed Childhood CNS Germinomas

Radiation Therapy

Source: Childhood Central Nervous System Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: October 8, 2024. Captured 2026-09-09.

CNS germinomas are highly radiosensitive and have been traditionally treated successfully with radiation therapy alone. Historically, patients with nondisseminated disease have been treated with craniospinal irradiation plus a boost to the region of the primary tumor. The dose of craniospinal irradiation has ranged from 24 Gy to 36 Gy, although studies have used lower doses. The local tumor dose of radiation therapy has ranged between 40 Gy and 50 Gy. Studies of lower-dose craniospinal irradiation have shown excellent outcomes.[19] This modification has resulted in 5-year OS rates exceeding 90%.[20]; [21][Level of evidence B4]; [22,23][Level of evidence C1] These excellent survival rates have allowed investigators to focus on reducing the radiation treatment volume and dose in an attempt to decrease late effects.[21,24,25]

Sources: 19 · 20 · 21 · Level of evidence B4 · 22 · 23 · Level of evidence C1 · 21 · 24 · 25

Patterns of relapse after craniospinal irradiation versus reduced-volume radiation therapy (whole-brain or whole-ventricular radiation therapy) have supported the omission of craniospinal irradiation for localized germinomas.[26-28] On the basis of these results, the treatment for patients with localized germinomas has been modified to cover the whole ventricular system (24 Gy) followed by a boost to the primary site (30–40 Gy), rather than to deliver radiation therapy to the entire craniospinal axis or even to the whole brain. This change has not resulted in worse outcomes and is expected to minimize the acute and long-term toxicity of radiation therapy. Focal radiation therapy directed only to the tumor volume, even after neoadjuvant chemotherapy, results in ventricular relapses; therefore, focal radiation therapy is not recommended.[25]

Sources: 26 · 28 · 25

Health professional · Treatment of Newly Diagnosed Childhood CNS Germinomas

Treatment Options Under Clinical Evaluation for Newly Diagnosed Childhood CNS Germinomas

Source: Childhood Central Nervous System Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: October 8, 2024. Captured 2026-09-09.

Early-phase therapeutic trials may be available for selected patients. These trials may be available via the Children’s Oncology Group, the Pediatric Brain Tumor Consortium, or other entities. Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Sources: Children’s Oncology Group · Pediatric Brain Tumor Consortium · NCI website · ClinicalTrials.gov website

Health professional

Treatment of Newly Diagnosed Childhood CNS Nongerminomatous Germ Cell Tumors

Source: Childhood Central Nervous System Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: October 8, 2024. Captured 2026-09-09.

Treatment options for newly diagnosed childhood central nervous system (CNS) nongerminomatous germ cell tumors (NGGCTs) include the following:

Chemotherapy followed by radiation therapy.

Sources: Chemotherapy followed by radiation therapy

Surgery, for tumors that partially respond to chemotherapy or for tumors that increase in size during or after therapy (possible growing teratoma syndrome).

Sources: Surgery

The optimal treatment regimen for CNS NGGCTs remains unclear.

The prognosis for children with CNS NGGCTs is inferior to that for children with germinomas, but the difference is diminishing with the addition of multimodality therapy. NGGCTs are radiosensitive, but patient survival rates after standard craniospinal irradiation alone has been poor, ranging from 20% to 45% at 5 years.[1] With the current treatment regimens, the 3-year to 5-year overall survival (OS) rates for patients with NGGCTs range from 75% to 90%.[2-4] In patients with NGGCTs who suffer tumor relapses, most occur within 3 years of diagnosis.[2]

Sources: 1 · 2 · 4 · 2

Health professional · Treatment of Newly Diagnosed Childhood CNS Nongerminomatous Germ Cell Tumors

Chemotherapy Followed by Radiation Therapy

Source: Childhood Central Nervous System Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: October 8, 2024. Captured 2026-09-09.

The use of chemotherapy before radiation therapy has increased survival rates. However, the specific chemotherapy regimen, length of therapy, and the optimal radiation field, timing, and dose remain under investigation.[1,5,6] Anticancer agents that have been used include carboplatin, etoposide, bleomycin, ifosfamide, and vinblastine in different combinations. Some investigators have proposed radiation therapy fields that are smaller than those used for craniospinal irradiation (e.g., whole-ventricular irradiation with a boost to the local tumor site) for patients with nondisseminated NGGCT. Controversy exists over the pattern of tumor relapse in patients treated with chemotherapy and focal or whole-ventricular radiation therapy.[1,7-9]

Sources: 1 · 5 · 6 · 1 · 7 · 9

Evidence (chemotherapy followed by radiation therapy):

A Children's Oncology Group (COG) study (ACNS0122 [NCT00047320]) evaluated neoadjuvant chemotherapy followed by radiation therapy for children with localized NGGCTs.[2] Neoadjuvant chemotherapy consisted of six courses with carboplatin/etoposide alternating with ifosfamide/etoposide. After chemotherapy was completed, responding patients received 36 Gy of craniospinal radiation therapy, with 54 Gy to the tumor bed.

Sources: ACNS0122 [NCT00047320] · 2

A Children's Oncology Group (COG) study (ACNS0122 [NCT00047320]) evaluated neoadjuvant chemotherapy followed by radiation therapy for children with localized NGGCTs.[2] Neoadjuvant chemotherapy consisted of six courses with carboplatin/etoposide alternating with ifosfamide/etoposide. After chemotherapy was completed, responding patients received 36 Gy of craniospinal radiation therapy, with 54 Gy to the tumor bed.

On the basis of a central review, 87% of patients showed either partial response (PR) or complete response (CR).

For the 102 eligible patients in the study, the 5-year event-free survival (EFS) rate was 84% (± 4%), and the OS rate was 93% (± 3%).

At 3 years, the EFS rate was 92% and the OS rate was 98% for all patients who achieved CR or PR either after induction chemotherapy or with the absence of malignant elements documented during second-look surgery.

The European SIOP-CNS-GCT-96 (NCT00293358) trial evaluated neoadjuvant chemotherapy consisting of four courses with cisplatin/etoposide/ifosfamide followed by focal radiation therapy (54 Gy) for patients with nonmetastatic disease.[3]

Sources: SIOP-CNS-GCT-96 (NCT00293358) · 3

The European SIOP-CNS-GCT-96 (NCT00293358) trial evaluated neoadjuvant chemotherapy consisting of four courses with cisplatin/etoposide/ifosfamide followed by focal radiation therapy (54 Gy) for patients with nonmetastatic disease.[3]

Patients with localized tumors (n = 116) demonstrated 5-year progression-free survival (PFS) rates of 72% (± 4%) and OS rates of 82% (± 4%).

Stratum 1 of the COG ACNS1123 (NCT01602666) study evaluated the efficacy of reduced-dose and reduced-volume radiation therapy in children and adolescents with localized NGGCTs who achieved PRs, CRs, and marker normalization after six cycles of chemotherapy. The main objective of this study was to evaluate the impact of reduced radiation therapy on PFS, with a goal of preserving neurocognitive function. Isolated spinal relapses occurred in 10% of patients in this trial, causing early stoppage of the protocol. This is compared with 8% of patients who developed a similar pattern of relapse in the ACNS0122 (NCT00047320) trial. Patients in this study received six cycles of chemotherapy with carboplatin and etoposide alternating with ifosfamide and etoposide. If a CR or PR with or without second-look surgery was achieved, the patient was eligible for reduced radiation therapy, defined as 30.6 Gy to the whole-ventricular field and a 54-Gy boost to the tumor bed, compared with 36 Gy of craniospinal irradiation plus a 54-Gy tumor-bed boost used in the ACNS0122 trial.[4,10]

Sources: ACNS1123 (NCT01602666) · ACNS0122 (NCT00047320) · 4 · 10

Stratum 1 of the COG ACNS1123 (NCT01602666) study evaluated the efficacy of reduced-dose and reduced-volume radiation therapy in children and adolescents with localized NGGCTs who achieved PRs, CRs, and marker normalization after six cycles of chemotherapy. The main objective of this study was to evaluate the impact of reduced radiation therapy on PFS, with a goal of preserving neurocognitive function. Isolated spinal relapses occurred in 10% of patients in this trial, causing early stoppage of the protocol. This is compared with 8% of patients who developed a similar pattern of relapse in the ACNS0122 (NCT00047320) trial. Patients in this study received six cycles of chemotherapy with carboplatin and etoposide alternating with ifosfamide and etoposide. If a CR or PR with or without second-look surgery was achieved, the patient was eligible for reduced radiation therapy, defined as 30.6 Gy to the whole-ventricular field and a 54-Gy boost to the tumor bed, compared with 36 Gy of craniospinal irradiation plus a 54-Gy tumor-bed boost used in the ACNS0122 trial.[4,10]

Of the 107 patients enrolled, 66 (61.7%) achieved a CR or PR and received reduced radiation therapy. The 3-year PFS rate was 87.8% (± 4.04%), and the OS rate was 92.4% (± 3.3%).

There were eight documented recurrences; six patients had distant spinal relapse alone and two patients had combined local-plus-distant relapse.

Patients with localized NGGCTs who achieved a CR or PR with chemotherapy and received reduced radiation therapy had a good PFS rate, similar to patients in the ACNS0122 trial who received craniospinal irradiation.

There was no significant difference in survival rates for NGGCT patients with localized disease in the two COG studies. The predominant site of relapse for patients in the ACNS1123 trial was in the spine, which was unique.[2,4]

Sources: 2 · 4

A subgroup analysis compared protons with photons to the whole ventricles for treating patients with NGGCTs.[11] Mean radiation doses and the doses to 40% of volumes, including the supratentorial brain, cerebellum, bilateral temporal, parietal, and frontal lobes, were significantly lower among patients who were treated with protons than patients who were treated with photons. Late effects data confirming a clinical benefit are not available.

Sources: 11

The current and prevailing controversy in the management of patients with newly diagnosed, localized NGGCTs—who have no evidence of dissemination and either a complete radiographic response to chemotherapy or have no evidence of disease before and after the initiation of chemotherapy—is the radiation volume. The SIOP-CNS-GCT-96 (NCT00293358) trial employed involved fields of radiation only for these patients with no radiographic evidence of residual or disseminated disease. Two COG protocols used either craniospinal or whole-ventricular fields of radiation plus a boost to the primary tumor. The incidence of isolated spinal relapses was similar in all of these studies, ranging from 8% to 11%.

Sources: SIOP-CNS-GCT-96 (NCT00293358)

Patients with relapsed NGGCTs are difficult to treat with curative intent, and their prognosis is guarded. Whether craniospinal irradiation or whole-ventricular plus spinal radiation should be included for all newly diagnosed NGGCT patients is an unresolved controversy and a major question for future clinical trials.

Health professional · Treatment of Newly Diagnosed Childhood CNS Nongerminomatous Germ Cell Tumors

Surgery

Source: Childhood Central Nervous System Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: October 8, 2024. Captured 2026-09-09.

A small percentage of patients treated with chemotherapy may have normalization of tumor markers with a less-than-complete radiographic response. Occasionally, a mass continues to expand in size even though tumor markers may have normalized. This condition, designated as growing teratoma syndrome, represents an accelerated growth of the mature teratoma components during or after treatment.[2,12-14] In such circumstances, complete surgical resection is the treatment of choice, as it provides histological confirmation and exclusion of mixed germ cell tumor components.

Sources: 2 · 12 · 14

A SIOP trial identified a significant OS advantage for patients without residual disease (5-year PFS rate, 85% ± 0.04% vs. 48% ± 0.07%), which underscores the important role of second-look surgery after chemotherapy and before irradiation.[3]

Sources: 3

A second-look surgery can help determine whether the residual mass contains teratoma, fibrosis, or residual NGGCT.[7,15] If second-look surgery finds mature teratoma or fibrosis after chemotherapy, the general approach is to proceed with radiation therapy as if the patient had achieved a CR to chemotherapy. However, if an active tumor is observed, then alternative treatment approaches are generally considered.[2]

Sources: 7 · 15 · 2

Health professional · Treatment of Newly Diagnosed Childhood CNS Nongerminomatous Germ Cell Tumors

Treatment Options Under Clinical Evaluation for Newly Diagnosed Childhood CNS NGGCTs

Source: Childhood Central Nervous System Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: October 8, 2024. Captured 2026-09-09.

Early-phase therapeutic trials may be available for selected patients. These trials may be available via the COG, the Pediatric Brain Tumor Consortium, or other entities. Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Sources: COG · Pediatric Brain Tumor Consortium · NCI website · ClinicalTrials.gov website

The following is an example of a national and/or institutional clinical trial that is currently being conducted:

ACNS2021 (NCT04684368) (A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT): This phase II trial studies the effect of chemotherapy combined with radiation therapy in treating patients with localized NGGCTs. The purpose of this study is to examine the tumor response to induction chemotherapy. Tumor response will then determine additional treatment options, including radiation therapy or high-dose chemotherapy and a stem cell transplant followed by radiation therapy.

Sources: ACNS2021 (NCT04684368)

Health professional

Treatment of Newly Diagnosed Childhood CNS Teratomas

Source: Childhood Central Nervous System Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: October 8, 2024. Captured 2026-09-09.

Teratomas are designated as mature or immature on the basis of the absence or presence of differentiated tissues. The Japanese Pediatric Brain Tumor Study Group stratifies teratomas for classification and intensity of treatment (chemotherapy and radiation) into a good-prognosis group (mature teratomas) and an intermediate-prognosis group (immature teratomas) (see Table 2), while the Children’s Oncology Group includes immature teratomas with other nongerminomatous germ cell tumors.

Sources: Table 2

Treatment options for newly diagnosed childhood central nervous system (CNS) teratomas include the following:

Gross-total resection.

Sources: Gross-total resection

Health professional · Treatment of Newly Diagnosed Childhood CNS Teratomas

Gross-Total Resection

Source: Childhood Central Nervous System Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: October 8, 2024. Captured 2026-09-09.

The primary treatment for teratomas is gross-total resection.[1,2][Level of evidence C1]

Sources: 1 · 2 · Level of evidence C1

Adjuvant treatment in the form of focal radiation therapy and/or adjuvant chemotherapy for patients with subtotally resected tumors is controversial. Small institutional series suggested a potential utility of stereotactic radiosurgery.[1,2][Level of evidence C1]

Sources: stereotactic radiosurgery · 1 · 2 · Level of evidence C1

Health professional

Treatment of Recurrent Childhood CNS Germ Cell Tumors

Source: Childhood Central Nervous System Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: October 8, 2024. Captured 2026-09-09.

Treatment options for recurrent childhood central nervous system (CNS) germ cell tumors (GCTs) include the following:

Chemotherapy followed by additional radiation therapy.

Sources: Chemotherapy followed by additional radiation therapy

High-dose chemotherapy with stem cell rescue with or without additional radiation therapy.

Sources: High-dose chemotherapy with stem cell rescue with or without additional radiation therapy

For patients who had localized germinomas at diagnosis and were treated with craniospinal and local boost radiation therapy, the most common form of relapse is at the primary site.[1] In contrast, the site of relapse is more variable in patients who relapse after chemotherapy and focal radiation therapy with or without whole-ventricular radiation to the primary site of disease. These patients have different combinations of local, disseminated ventricular, cerebral, leptomeningeal, and spinal relapse.[1,2]

Sources: 1 · 1 · 2

Patients with disseminated germinomas and nongerminomatous germ cell tumors (NGGCTs) also may have complex patterns of relapse, including local and/or disseminated intracranial or intraspinal relapse after treatment with craniospinal radiation therapy alone or preirradiation chemotherapy with various volumes and doses of radiation therapy.[1-3]

Sources: 1 · 3

Enrollment on clinical trials should be considered for all patients with recurrent disease. Information about ongoing National Cancer Institute (NCI)–supported clinical trials is available from the NCI website.

Sources: NCI website

Health professional · Treatment of Recurrent Childhood CNS Germ Cell Tumors

Chemotherapy Followed by Additional Radiation Therapy

Source: Childhood Central Nervous System Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: October 8, 2024. Captured 2026-09-09.

Patients with germinomas that were treated initially with chemotherapy only can benefit from chemotherapy followed by radiation therapy at the time of relapse.[4,5] Reirradiation, including radiosurgery, after chemotherapy at recurrence has been used.[5-9]

Sources: 4 · 5 · radiosurgery · 5 · 9

Health professional · Treatment of Recurrent Childhood CNS Germ Cell Tumors

High-Dose Chemotherapy With Stem Cell Rescue With or Without Additional Radiation Therapy

Source: Childhood Central Nervous System Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: October 8, 2024. Captured 2026-09-09.

For patients with pure germinomas who previously received radiation therapy, myeloablative chemotherapy with stem cell rescue has been used. High-dose chemotherapy and autologous stem cell rescue may also have curative potential for some patients with relapsed systemic NGGCTs.[7,9-13]

Sources: 7 · 9 · 13

Health professional · Treatment of Recurrent Childhood CNS Germ Cell Tumors

Treatment Options Under Clinical Evaluation for Recurrent Childhood CNS GCTs

Source: Childhood Central Nervous System Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: October 8, 2024. Captured 2026-09-09.

There are limited clinical trials available for patients with recurrent NGGCTs. Early-phase therapeutic trials may be available for selected patients. These trials may be available via the Children’s Oncology Group (COG), the Pediatric Brain Tumor Consortium, or other entities. Information about NCI-supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Sources: Children’s Oncology Group (COG) · Pediatric Brain Tumor Consortium · NCI website · ClinicalTrials.gov website

For patients · Stages of Childhood CNS Germ Cell Tumors

Sometimes childhood central nervous system germ cell tumors come back after treatment.

Source: Childhood Central Nervous System Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 6, 2024. Captured 2026-09-09.

The tumors usually recur (come back) where they first formed. The tumors may also come back in other places and/or in the meninges (thin layers of tissue that cover and protect the brain and spinal cord).

Sources: meninges · tissue

For patients

Treatment Option Overview

Source: Childhood Central Nervous System Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 6, 2024. Captured 2026-09-09.

For patients · Treatment Option Overview

Key Points

Source: Childhood Central Nervous System Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 6, 2024. Captured 2026-09-09.

There are different types of treatment for children with central nervous system (CNS) germ cell tumors.

Children with CNS germ cell tumors should have their treatment planned by a team of health care providers who are experts in treating cancer in children.

The following types of treatment are used:

The following types of treatment are used:

Radiation therapy

Chemotherapy

Surgery

High-dose chemotherapy with stem cell rescue

New types of treatment are being tested in clinical trials.

Treatment for childhood CNS germ cell tumors may cause side effects.

Patients may want to think about taking part in a clinical trial.

Patients can enter clinical trials before, during, or after starting their cancer treatment.

Follow-up care may be needed.

For patients · Treatment Option Overview

There are different types of treatment for children with central nervous system (CNS) germ cell tumors.

Source: Childhood Central Nervous System Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 6, 2024. Captured 2026-09-09.

Different types of treatment are available for children with central nervous system (CNS) germ cell tumors. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for people with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment.

Sources: central nervous system · germ cell tumors · standard · clinical trials · research study · cancer

Because cancer in children is rare, taking part in a clinical trial should be considered. Some clinical trials are open only to patients who have not started treatment.

For patients · Treatment Option Overview

Children with CNS germ cell tumors should have their treatment planned by a team of health care providers who are experts in treating cancer in children.

Source: Childhood Central Nervous System Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 6, 2024. Captured 2026-09-09.

Treatment will be overseen by a pediatric oncologist and/or a radiation oncologist. A pediatric oncologist is a doctor who specializes in treating children with cancer. A radiation oncologist specializes in treating cancer with radiation therapy. These doctors work with other pediatric health care providers who are experts in treating children with CNS germ cell tumors and who specialize in certain areas of medicine. These may include the following specialists:

Sources: pediatric oncologist · radiation oncologist · radiation therapy · pediatric · health care providers · medicine · specialists

Pediatrician.

Sources: Pediatrician

Pediatric neurosurgeon.

Sources: neurosurgeon

Neurologist.

Sources: Neurologist

Endocrinologist.

Sources: Endocrinologist

Ophthalmologist.

Sources: Ophthalmologist.

Pediatric nurse specialist.

Sources: Pediatric nurse specialist

Rehabilitation specialist.

Sources: Rehabilitation specialist

Psychologist.

Sources: Psychologist

Social worker.

Sources: Social worker

Fertility specialists.

Sources: Fertility specialists

For patients · Treatment Option Overview

The following types of treatment are used:

Source: Childhood Central Nervous System Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 6, 2024. Captured 2026-09-09.

For patients · Treatment Option Overview / The following types of treatment are used:

Radiation therapy

Source: Childhood Central Nervous System Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 6, 2024. Captured 2026-09-09.

Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing.

Sources: x-rays · radiation · cells

External radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer. Certain ways of giving radiation therapy can help keep radiation from damaging nearby healthy tissue. This type of radiation therapy may include:

Sources: External radiation therapy · tissue

Stereotactic radiosurgery: Stereotactic radiosurgery is a type of external radiation therapy. A rigid head frame is attached to the skull to keep the head still during the radiation treatment. A machine aims a single large dose of radiation directly at the tumor. This procedure does not involve surgery. It is also called stereotaxic radiosurgery, radiosurgery, and radiation surgery.

Sources: Stereotactic radiosurgery · skull · dose · tumor · surgery

Radiation therapy to the brain can affect growth and development in young children. Certain ways of giving radiation therapy can lessen the damage to healthy brain tissue. For children younger than 3 years, chemotherapy may be given instead. This can delay or reduce the need for radiation therapy.

Sources: brain · chemotherapy

For patients · Treatment Option Overview / The following types of treatment are used:

Chemotherapy

Source: Childhood Central Nervous System Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 6, 2024. Captured 2026-09-09.

Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy).

Sources: drugs · injected · vein · systemic chemotherapy

For patients · Treatment Option Overview / The following types of treatment are used:

Surgery

Source: Childhood Central Nervous System Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 6, 2024. Captured 2026-09-09.

Whether surgery to remove the tumor can be done depends on where the tumor is in the brain. Surgery to remove the tumor may cause severe, long-term side effects.

Sources: side effects

Surgery may be done to remove teratomas and may be used for germ cell tumors that come back. After the doctor removes all the cancer that can be seen at the time of the surgery, some patients may be given chemotherapy or radiation therapy after surgery to kill any cancer cells that are left. Treatment given after the surgery, to lower the risk that the cancer will come back, is called adjuvant therapy.

Sources: teratomas · adjuvant therapy

For patients · Treatment Option Overview / The following types of treatment are used:

High-dose chemotherapy with stem cell rescue

Source: Childhood Central Nervous System Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 6, 2024. Captured 2026-09-09.

High doses of chemotherapy are given to kill cancer cells. Healthy cells, including blood-forming cells, are also destroyed by the cancer treatment. Stem cell transplant is a treatment to replace the blood-forming cells. Stem cells (immature blood cells) are removed from the blood or bone marrow of the patient and are frozen and stored. After the patient completes chemotherapy, the stored stem cells are thawed and given back to the patient through an infusion. These reinfused stem cells grow into (and restore) the body's blood cells.

Sources: blood · Stem cell transplant · Stem cells · bone marrow · infusion

For patients · Treatment Option Overview

New types of treatment are being tested in clinical trials.

Source: Childhood Central Nervous System Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 6, 2024. Captured 2026-09-09.

Information about clinical trials is available from the NCI website.

Sources: NCI website

For patients · Treatment Option Overview

Treatment for childhood CNS germ cell tumors may cause side effects.

Source: Childhood Central Nervous System Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 6, 2024. Captured 2026-09-09.

To learn more about side effects that begin during treatment for cancer, visit Side Effects.

Sources: side effects · Side Effects

Side effects from cancer treatment that begin after treatment and continue for months or years are called late effects. Late effects of cancer treatment may include:

Sources: late effects

Physical problems, including:

Physical problems, including:

Vision problems.

Endocrine problems, such as diabetes insipidus.

Sources: Endocrine · diabetes insipidus

Blood vessel problems, such as stroke.

Sources: Blood vessel · stroke

Changes in mood, feelings, thinking, learning, or memory.

Second cancers (new types of cancer).

Sources: Second cancers

Some late effects may be treated or controlled. Talk with your child's doctors about the possible late effects caused by some treatments. Learn more at Late Effects of Treatment for Childhood Cancer.

Sources: Late Effects of Treatment for Childhood Cancer

For patients · Treatment Option Overview

Patients may want to think about taking part in a clinical trial.

Source: Childhood Central Nervous System Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 6, 2024. Captured 2026-09-09.

For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment.

Sources: clinical trial · standard treatment

Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.

Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.

For patients · Treatment Option Overview

Patients can enter clinical trials before, during, or after starting their cancer treatment.

Source: Childhood Central Nervous System Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 6, 2024. Captured 2026-09-09.

Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.

Sources: side effects

Clinical trials are taking place in many parts of the country. Information about clinical trials supported by NCI can be found on NCI’s clinical trials search webpage. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.

Sources: clinical trials search · ClinicalTrials.gov

For patients · Treatment Option Overview

Follow-up care may be needed.

Source: Childhood Central Nervous System Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 6, 2024. Captured 2026-09-09.

As your child goes through treatment, they will have follow-up tests or check-ups. Some of the tests that were done to diagnose the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.

Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your child's condition has changed or if the cancer has recurred (come back).

Children whose cancer affected their pituitary gland when the cancer was diagnosed will usually need to have their blood hormone levels checked. If the blood hormone level is low, replacement hormone medicine is given.

Sources: pituitary gland · hormone

Children who had a high tumor marker level (alpha-fetoprotein or beta-human chorionic gonadotropin) when the cancer was diagnosed usually need to have their blood tumor marker level checked. If the tumor marker level increases after initial treatment, the tumor may have recurred.

Sources: tumor marker · alpha-fetoprotein · beta-human chorionic gonadotropin

For patients

Treatment of Childhood CNS Germinomas

Source: Childhood Central Nervous System Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 6, 2024. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of newly diagnosed central nervous system (CNS) germinomas may include:

Sources: diagnosed · central nervous system · germinomas

Chemotherapy followed by radiation therapy.

Sources: Chemotherapy · radiation therapy

Radiation therapy to the whole brain including the ventricles (fluid-filled spaces of the brain) and spinal cord. A higher dose of radiation is given to the tumor than the area around the tumor.

Sources: brain · ventricles · fluid · spinal cord · dose · radiation · tumor

Radiation therapy to the ventricles and the tumor.

For patients

Treatment of Childhood CNS Nongerminomas

Source: Childhood Central Nervous System Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 6, 2024. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

It is not clear what treatment is best for newly diagnosed central nervous system (CNS) nongerminomas.

Sources: diagnosed · central nervous system · nongerminomas

Treatment of choriocarcinoma, embryonal carcinoma, yolk sac tumor, or mixed germ cell tumor may include:

Sources: choriocarcinoma · embryonal · carcinoma · yolk sac tumor · mixed germ cell tumor

Chemotherapy followed by radiation therapy.

Sources: Chemotherapy · radiation therapy

Surgery. If a mass remains after chemotherapy that continues to grow and tumor marker levels are normal (called growing teratoma syndrome), surgery may be needed to check if the mass is part teratoma, fibrosis, or a growing tumor.

Sources: Surgery · mass · tumor marker · surgery · fibrosis · tumor

Surgery. If a mass remains after chemotherapy that continues to grow and tumor marker levels are normal (called growing teratoma syndrome), surgery may be needed to check if the mass is part teratoma, fibrosis, or a growing tumor.

If the mass is a mature teratoma or fibrosis, radiation therapy is given.

Sources: mature teratoma

If the mass is a growing tumor, other treatments may be given.

A clinical trial of chemotherapy with radiation therapy to treat patients with CNS nongerminomas that have not spread.

Sources: clinical trial

For patients

Treatment of Childhood CNS Teratomas

Source: Childhood Central Nervous System Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 6, 2024. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of newly diagnosed mature and immature central nervous system (CNS) teratomas may include:

Sources: diagnosed · mature · immature · central nervous system · teratomas

Surgery to remove as much of the tumor as possible.

Sources: Surgery · tumor

For patients

Treatment of Recurrent Childhood CNS Germ Cell Tumors

Source: Childhood Central Nervous System Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 6, 2024. Captured 2026-09-09.

Treatment of recurrent childhood central nervous system (CNS) germ cell tumors may include:

Sources: recurrent · central nervous system · germ cell tumors

Chemotherapy followed by radiation therapy, for germinomas.

Sources: Chemotherapy · radiation therapy · germinomas

High-dose chemotherapy with stem cell rescue using the patient's stem cells, with or without more radiation therapy, for germinomas and nongerminomas.

Sources: High-dose chemotherapy · stem cell rescue · stem cells · nongerminomas

Studies

Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors

NCT00047320 · COMPLETED · phase2

Brain Tumor, Central Nervous System Tumors, Childhood Germ Cell Tumor

ClinicalTrials.gov record

Combination Chemotherapy and Radiation Therapy in Treating Patients With Germ Cell Tumors in the Brain

NCT00293358 · COMPLETED · phase3

Brain and Central Nervous System Tumors

ClinicalTrials.gov record

Sunitinib in Treating Young Patients With Refractory Solid Tumors

NCT00387920 · COMPLETED · phase1

Central Nervous System Metastases, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor, Childhood Central Nervous System Germ...

ClinicalTrials.gov record

Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment

NCT00929903 · COMPLETED · phase1

Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor, Childhood Central Nervous System Germ Cell Tumor, Childhood Central Nervous...

ClinicalTrials.gov record

Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors

NCT01602666 · COMPLETED · phase2

Central Nervous System Nongerminomatous Germ Cell Tumor, Childhood Germinoma

ClinicalTrials.gov record

A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

NCT04684368 · RECRUITING · phase2

Central Nervous System Nongerminomatous Germ Cell Tumor, Choriocarcinoma, Embryonal Carcinoma, Immature Teratoma, Malignant Teratoma, Mixed Germ Cell Tumor, Pineal Region Germ...

ClinicalTrials.gov record

Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer

NCT00492089 · COMPLETED · phase2

Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Meningioma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Central Nervous...

ClinicalTrials.gov record

Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer

NCT01037790 · COMPLETED · phase2

Adult Solid Tumor, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Adult Central Nervous System Germ Cell Tumor, Adult Teratoma, Benign Teratoma, Estrogen...

ClinicalTrials.gov record

Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors

NCT01808534 · TERMINATED · phase2

Adult Central Nervous System Germ Cell Tumor, Adult Teratoma, Malignant Extragonadal Germ Cell Tumor, Malignant Extragonadal Non-Seminomatous Germ Cell Tumor, Extragonadal...

ClinicalTrials.gov record

Disease and treatment settings

Childhood Central Nervous System Germ Cell Tumors

Disease and treatment setting

Treatment of Newly Diagnosed Childhood CNS Germinomas

Childhood Central Nervous System Germ Cell Tumors

Disease and treatment setting

Central Nervous System Germ Cell Tumors in children and adolescents

recurrent Childhood Central Nervous System Germ Cell Tumors

Disease and treatment setting

Treatment of Recurrent Childhood CNS Germ Cell Tumors